当前位置: 首页 >> 检索结果
81. Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK).
作者: Cindy L J Weinstein.;Paula Sliwinska-Stanczyk.;Tomas Hála.;Marina Stanislav.;Anjela Tzontcheva.;Ruji Yao.;Yuliya Berd.;Sean P Curtis.;George Philip.
来源: Rheumatology (Oxford). 2023年62卷11期3601-3609页
The GO-BACK study was designed to evaluate the efficacy and safety of golimumab (GLM) treatment withdrawal in adults with non-radiographic axial spondyloarthritis (nr-axSpA) who demonstrate inactive disease during a 10-month open-label (OL) GLM run-in.
82. A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.
作者: Darren Bentley.;Benjamin A Fisher.;Francesca Barone.;Fabrice A Kolb.;Gemma Attley.
来源: Rheumatology (Oxford). 2023年62卷11期3644-3653页
Primary SS (pSS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSS.
83. Self-monitoring combined with patient-initiated care in RA patients with low disease activity: cost-effectiveness analysis of an RCT.
作者: Bart F Seppen.;Marjolein J E Greuter.;Jimmy Wiegel.;Marieke M Ter Wee.;Maarten Boers.;Michael T Nurmohamed.;Wouter H Bos.
来源: Rheumatology (Oxford). 2023年62卷10期3366-3372页
Self-monitoring and patient-initiated care (PIC) leads to fewer outpatient clinic visits in patients with established RA with low disease activity (LDA) while healthcare outcomes are similar. This study assesses the cost-effectiveness of PIC with self-monitoring.
84. A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
作者: Deborah J Griffiths-Jones.;Yvonne Sylvestre Garcia.;W David Ryder.;John D Pauling.;Frances Hall.;Peter Lanyon.;Smita Bhat.;Karen Douglas.;Harsha Gunawardena.;Mohammed Akil.;Marina Anderson.;Bridget Griffiths.;Francesco Del Galdo.;Hazem Youssef.;Rajan Madhok.;Barbara Arthurs.;Maya Buch.;Kim Fligelstone.;Mohammed Zubair.;Justin C Mason.;Christopher P Denton.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2023年62卷9期3133-3138页
Although the painful and disabling features of early diffuse cutaneous SSc (dcSSc) have an inflammatory basis and could respond to corticosteroids, corticosteroids are a risk factor for scleroderma renal crisis. Whether or not they should be prescribed is therefore highly contentious. Our aim was to examine safety and efficacy of moderate-dose prednisolone in early dcSSc.
85. A multidisciplinary lifestyle program for rheumatoid arthritis: the 'Plants for Joints' randomized controlled trial.
作者: Wendy Walrabenstein.;Carlijn A Wagenaar.;Marike van der Leeden.;Franktien Turkstra.;Jos W R Twisk.;Maarten Boers.;Henriët van Middendorp.;Peter J M Weijs.;Dirkjan van Schaardenburg.
来源: Rheumatology (Oxford). 2023年62卷8期2683-2691页
To determine the effect of a multidisciplinary lifestyle program in patients with RA with low-moderate disease activity.
86. Prospective double-blind study on the value of musculoskeletal ultrasound by dermatologists as a screening instrument for psoriatic arthritis.
作者: Jakub Grobelski.;Dagmar Wilsmann-Theis.;Pantelis Karakostas.;Charlotte Behning.;Peter Brossart.;Valentin S Schäfer.
来源: Rheumatology (Oxford). 2023年62卷8期2724-2731页
This study evaluated musculoskeletal ultrasound (MSUS) use by dermatologists previously trained on a novel handheld, chip-based ultrasound device (HHUD) to screen for early PsA.
87. Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.
作者: Arnaud Constantin.;Roberto Caporali.;Christopher J Edwards.;João Eurico Fonseca.;Florenzo Iannone.;Edward Keystone.;Hendrik Schulze-Koops.;Taek Kwon.;Seungmin Kim.;SangWook Yoon.;Dong-Hyeon Kim.;Gahee Park.;Dae Hyun Yoo.
来源: Rheumatology (Oxford). 2023年62卷8期2838-2844页
The primary endpoint of the pivotal phase III study of infliximab (IFX) s.c. demonstrated non-inferiority of s.c. to i.v. IFX, based on 28-joint DAS-CRP (DAS28-CRP) improvement at week (W) 22 (NCT03147248). This post-hoc analysis investigated whether numerical differences in efficacy outcomes at W30/54 were statistically significant, using conservative imputation methods.
88. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
作者: Andrew Östör.;Filip Van den Bosch.;Kim Papp.;Cecilia Asnal.;Ricardo Blanco.;Jacob Aelion.;Wenjing Lu.;Zailong Wang.;Ahmed M Soliman.;Ann Eldred.;Byron Padilla.;Alan Kivitz.
来源: Rheumatology (Oxford). 2023年62卷6期2122-2129页
PsA is a chronic inflammatory disease in which the skin and joints are affected. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated.
89. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
作者: Lars Erik Kristensen.;Mauro Keiserman.;Kim Papp.;Leslie McCasland.;Douglas White.;Wenjing Lu.;Ahmed M Soliman.;Ann Eldred.;Lisa Barcomb.;Frank Behrens.
来源: Rheumatology (Oxford). 2023年62卷6期2113-2121页
PsA is a chronic disease with heterogeneous clinical manifestations requiring treatment options with long-term efficacy and safety. In this follow-up analysis, the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or more conventional synthetic DMARDs (csDMARD-IR) were evaluated.
90. Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.
作者: Linda Hartman.;Linda A Rasch.;Samina A Turk.;Marieke M Ter Wee.;Pit J S M Kerstens.;Conny J van der Laken.;Michael T Nurmohamed.;Dirkjan van Schaardenburg.;Lilian H D van Tuyl.;Alexandre E Voskuyl.;Maarten Boers.;Willem F Lems.
来源: Rheumatology (Oxford). 2023年62卷6期2098-2105页
The aim of this study was to investigate the effect of treat-to-target combination therapy with intensification at 13 weeks in early RA.
91. Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial.
作者: Kristina Lend.;Ronald F van Vollenhoven.;Jon Lampa.;Merete Lund Hetland.;Espen A Haavardsholm.;Dan Nordström.;Michael Nurmohamed.;Bjorn Gudbjornsson.;Anna Rudin.;Mikkel Østergaard.;Till Uhlig.;Gerdur Grondal.;Kim Hørslev-Petersen.;Marte S Heiberg.;Tuulikki Sokka-Isler.;Frieda A Koopman.;Jos W R Twisk.;Irene van der Horst-Bruinsma.
来源: Lancet Rheumatol. 2022年4卷10期e688-e698页
Rheumatoid arthritis is a chronic inflammatory disease with a well-recognised female preponderance. In this post-hoc analysis of the NORD-STAR trial, we aimed to examine sex differences in remission rates with three different biological treatments combined with methotrexate versus active conventional treatment over 24 weeks, in patients with early rheumatoid arthritis.
92. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
作者: Linda Hartman.;José A P da Silva.;Frank Buttgereit.;Maurizio Cutolo.;Daniela Opris-Belinski.;Zoltan Szekanecz.;Pavol Masaryk.;Marieke J H Voshaar.;Martijn W Heymans.;Willem F Lems.;Désirée M F M van der Heijde.;Maarten Boers.
来源: Rheumatology (Oxford). 2023年62卷5期1824-1833页
To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo.
93. Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.
作者: Tae-Hwan Kim.;Mitsumasa Kishimoto.;James Cheng-Chung Wei.;Haeyoun Jeong.;Akiyo Nozaki.;Shigeto Kobayashi.
来源: Rheumatology (Oxford). 2023年62卷5期1851-1859页
To evaluate the long-term efficacy and safety of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis (axSpA).
94. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
作者: Walter P Maksymowych.;Xenofon Baraliakos.;Robert G Lambert.;Robert Landewé.;David Sandoval.;Hilde Carlier.;Jeffrey Lisse.;Xiaoqi Li.;Maja Hojnik.;Mikkel Østergaard.
来源: Lancet Rheumatol. 2022年4卷9期e626-e634页
There is limited understanding regarding the inhibition of structural damage in the sacroiliac joint of patients with non-radiographic axial spondyloarthritis. This study evaluated the effect of the interleukin-17A inhibitor ixekizumab versus placebo on structural lesions in the sacroiliac joints as assessed by MRI at week 16 in patients with non-radiographic axial spondyloarthritis from the COAST-X study.
95. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
作者: Ian N Bruce.;Ronald F van Vollenhoven.;Eric F Morand.;Richard A Furie.;Susan Manzi.;William B White.;Gabriel Abreu.;Raj Tummala.
来源: Rheumatology (Oxford). 2023年62卷4期1526-1534页
Glucocorticoid sparing is a key priority for SLE management. We evaluated the effects of sustained glucocorticoid tapering in patients with SLE.
96. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
作者: Eduardo Mysler.;Yoshiya Tanaka.;Arthur Kavanaugh.;Daniel Aletaha.;Peter C Taylor.;In-Ho Song.;Tim Shaw.;Yanna Song.;Ryan DeMasi.;Mira Ali.;Roy Fleischmann.
来源: Rheumatology (Oxford). 2023年62卷5期1804-1813页
Evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response.
97. Association between popliteal artery wall thickness and structural progression in patients with symptomatic knee osteoarthritis.
作者: Yuanyuan Wang.;Ega Wirayoda Pontoh.;Sultana Monira Hussain.;Yuan Z Lim.;Graeme Jones.;Catherine L Hill.;Anita E Wluka.;Andrew Tonkin.;Changhai Ding.;Flavia M Cicuttini.
来源: Rheumatology (Oxford). 2023年62卷4期1645-1651页
There is increasing evidence for the involvement of vascular disease in the pathogenesis of knee OA. Popliteal artery wall thickness can be used as a surrogate marker of atherosclerosis. We examined the association between popliteal artery wall thickness and knee cartilage volume in individuals with symptomatic knee OA.
98. The effect of group-based cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: a randomized controlled trial.
作者: Kristine M Latocha.;Katrine B Løppenthin.;Mikkel Østergaard.;Poul J Jennum.;Merete L Hetland.;Henrik Røgind.;Tine Lundbak.;Julie Midtgaard.;Robin Christensen.;Bente A Esbensen.
来源: Rheumatology (Oxford). 2023年62卷3期1097-1107页
The primary objective was to compare the effect of cognitive behavioural therapy for insomnia (CBT-I) to usual care on sleep efficiency, measured by polysomnography (PSG) immediately after the intervention at week 7. Secondary objectives included comparing the longer-term effect on sleep- and RA-related outcomes at week 26.
99. Serum biomarkers in prednisolone-treated hand osteoarthritis patients.
作者: Lotte A van de Stadt.;Féline P B Kroon.;Christian F Thudium.;Anne C Bay-Jensen.;Margreet Kloppenburg.
来源: Rheumatology (Oxford). 2023年62卷3期1350-1355页
To investigate whether biomarkers are modulated by prednisolone treatment in patients with hand OA and whether they can predict response to prednisolone.
100. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
作者: Satoshi Ebata.;Ayumi Yoshizaki.;Koji Oba.;Kosuke Kashiwabara.;Keiko Ueda.;Yukari Uemura.;Takeyuki Watadani.;Takemichi Fukasawa.;Shunsuke Miura.;Asako Yoshizaki-Ogawa.;Naoko Okiyama.;Masanari Kodera.;Minoru Hasegawa.;Shinichi Sato.
来源: Lancet Rheumatol. 2022年4卷8期e546-e555页
Results from the double-blind phase 2 DESIRES trial showed that rituximab improves skin thickening in systemic sclerosis. Here, we present the findings of a subsequent 24-week open-label extension phase.
|